Top Page
Firebrick Pharma Limited
(Sydney:FRE)
Firebrick Pharma Limited (FRE) vs. iShares MSCI Australia ETF (EWA)
Firebrick Pharma Limited Business Overview & Revenue Model
Firebrick Pharma Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.13M | 14.52K | 830.00 | 4.12K | 422.00K | 508.98K | Gross Profit |
| 1.04M | -22.78K | 830.00 | 4.12K | 421.48K | 508.68K | EBIT |
| -1.46M | -3.93M | -6.86M | -3.79M | -2.86M | -2.01M | EBITDA |
| -1.59M | -1.08M | -6.81M | -3.50M | -2.44M | -1.50M | Net Income Common Stockholders |
| -1.72M | -1.18M | -6.80M | -3.80M | -2.44M | -1.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.16M | 824.78K | 2.35M | 7.14M | 11.16M | 92.70K | Total Assets |
| 1.76M | 2.41M | 2.98M | 8.73M | 11.77M | 654.81K | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.41K | Net Debt |
| -1.15M | -824.78K | -2.35M | -7.14M | -10.88M | -38.29K | Total Liabilities |
| 214.80K | 291.07K | 506.44K | 450.10K | 214.80K | 264.22K | Stockholders Equity |
| 1.55M | 2.12M | 2.48M | 8.28M | 11.55M | 390.60K |
| Cash Flow | Free Cash Flow | ||||
| -1.99M | -2.35M | -5.78M | -4.23M | -1.95M | -985.01K | Operating Cash Flow |
| -1.93M | -2.34M | -5.78M | -4.20M | -1.94M | -985.01K | Investing Cash Flow |
| -66.49K | -134.00 | -1.62K | -32.54K | -16.07K | 0.00 | Financing Cash Flow |
| 1.60M | 815.21K | 996.65K | 10.23M | 3.01M | 500.25K |
Firebrick Pharma Limited Technical Analysis
Firebrick Pharma Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
38 Underperform | ― | -111.71% | ― | ― | 67.55% | ||
| $850.23M | 72.50 | 9.23% | ― | ― | ― | ||
| $3.71M | ― | -67.69% | ― | ― | ― | ||
| $256.80M | ― | -31.16% | ― | ― | ― | ||
53 Neutral | AU$647.09M | ― | -56.99% | ― | 10.76% | -195.89% |
Firebrick Pharma Limited Corporate Events
Firebrick Pharma Limited has successfully launched its Nasodine Nasal Spray in Singapore, expanding its availability to 125 Guardian pharmacies and gaining support from local doctors. The company also reported significant growth in online sales in the US, driven by marketing strategies and promotions, indicating strong market adoption and positioning for future growth.
Firebrick Pharma Limited has issued 189,000 ordinary fully paid shares following the exercise of unlisted options at a price of $0.01 per share. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant provisions, ensuring transparency and adherence to regulatory standards.
Firebrick Pharma Limited has announced the quotation of 189,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of March 28, 2025. This move reflects the company’s efforts to enhance its financial standing and market presence, potentially impacting its operations and stakeholder interests positively.
Firebrick Pharma Limited, a company in the pharmaceutical industry, has announced that Pharma Nutria N.A., Inc. has become a substantial holder of its shares. Pharma Nutria N.A., Inc. acquired 11,578,947 ordinary shares, representing a 5.22% voting power in Firebrick Pharma, for a consideration of $1,100,000. This acquisition marks a significant investment and could impact Firebrick Pharma’s market positioning and stakeholder interests.
Firebrick Pharma Limited has announced a change in the interests of a substantial holder, Stephen Francis Goodall and related parties. The change, effective from March 5, 2025, reflects a dilutionary effect due to a private placement, resulting in an adjusted voting power. This development may impact the company’s shareholder structure and influence its governance dynamics.
Firebrick Pharma Limited has announced a change in the substantial holding of shares by Peter Laurence Molloy and related parties. The change, effective March 5, 2025, resulted in a decrease in voting power from 15.80% to 14.35% due to a dilutionary effect from a private placement. This adjustment in shareholding could impact the company’s control dynamics and influence within the market.
Firebrick Pharma Limited has issued 11,578,947 ordinary fully paid shares at $0.095 per share as part of a recent placement. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating no excluded information affecting investor assessments. This move is part of Firebrick’s broader strategy to strengthen its financial position and support its ongoing expansion efforts.
Firebrick Pharma Limited has announced the quotation of 11,578,947 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of March 5, 2025. This move is part of a previously announced transaction and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s visibility and access to capital.
Firebrick Pharma Limited has announced a proposed issue of 11,578,947 fully paid ordinary securities, with the issue date set for March 6, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market position by increasing its capital base and providing additional resources for its operations.
Firebrick Pharma Limited has secured a $1.1 million strategic investment from Pharma Nutria N.A., Inc., a partner associated with its licensing partner in the Philippines. This investment will support the marketing of Nasodine Nasal Spray in Singapore, new product development, and other operational costs, highlighting the strong partnership and confidence in Firebrick’s growth potential and innovative products.
Firebrick Pharma Limited announced an investor webinar scheduled for February 25, 2025, to discuss half-year results, the launch of Nasodine Nasal Spray in new markets, and future plans for 2025. This event provides shareholders and potential investors with updates on the company’s strategy and an opportunity for engagement through a Q&A session.
Firebrick Pharma Limited reported its financial results for the half-year ending December 31, 2024, showing a revenue increase to $196,752, up from zero in the previous period. Despite the revenue growth, the company faced a significant increase in losses, with a 60.99% rise in loss after tax to $1,446,378. No dividends were declared, and the auditor’s report highlighted a material uncertainty regarding the company’s ability to continue as a going concern.
Firebrick Pharma Limited has announced a License and Distribution Agreement with Makans Limited to promote and sell its Nasodine Nasal Spray in Fiji and the South Pacific. This partnership, with Fiji’s largest pharmaceutical wholesaler, is expected to boost Nasodine’s market reach to a population of around two million, potentially increasing sales significantly. Makans will handle marketing, distribution, and regulatory requirements, paying Firebrick a handling fee and license fee per unit sold.